Richard H Myers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6398424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 1993, 72, 971-983.	13.5	7,960
2	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	9.4	2,634
3	Neuropathological Classification of Huntington's Disease. Journal of Neuropathology and Experimental Neurology, 1985, 44, 559-577.	0.9	2,258
4	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	9.4	1,685
5	Trinucleotide repeat length instability and age of onset in Huntington's disease. Nature Genetics, 1993, 4, 387-392.	9.4	1,008
6	Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations. Cell, 2011, 146, 318-331.	13.5	703
7	CAG repeat number governs the development rate of pathology in Huntington's disease. Annals of Neurology, 1997, 41, 689-692.	2.8	605
8	Familial lipoprotein disorders in patients with premature coronary artery disease Circulation, 1992, 85, 2025-2033.	1.6	560
9	Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study. Annals of Neurology, 1991, 30, 637-649.	2.8	550
10	Evidence for a Gene Influencing Blood Pressure on Chromosome 17. Hypertension, 2000, 36, 477-483.	1.3	534
11	Evidence for Association and Genetic Linkage of the Angiotensin-Converting Enzyme Locus With Hypertension and Blood Pressure in Men but Not Women in the Framingham Heart Study. Circulation, 1998, 97, 1766-1772.	1.6	500
12	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genetics, 2012, 8, e1002548.	1.5	495
13	Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature, 2016, 533, 95-99.	13.7	466
14	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Human Genetics, 2009, 124, 593-605.	1.8	410
15	Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature, 1990, 347, 194-197.	13.7	407
16	Genetic Signatures of Exceptional Longevity in Humans. PLoS ONE, 2012, 7, e29848.	1.1	340
17	CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. Cell, 2019, 178, 887-900.e14.	13.5	301

18 Huntington's disease genetics. NeuroRx, 2004, 1, 255-262.

6.0 296

#	Article	IF	CITATIONS
19	Parental history is an independent risk factor for coronary artery disease: The Framingham Study. American Heart Journal, 1990, 120, 963-969.	1.2	294
20	A Genome-Wide Association Study of Pulmonary Function Measures in the Framingham Heart Study. PLoS Genetics, 2009, 5, e1000429.	1.5	292
21	HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Human Molecular Genetics, 2005, 14, 2871-2880.	1.4	274
22	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Science Translational Medicine, 2018, 10, .	5.8	273
23	Metaâ€enalysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> . Annals of Neurology, 2012, 71, 370-384.	2.8	264
24	Genetic Associations in Age-Related Hearing Thresholds. JAMA Otolaryngology, 1999, 125, 654.	1.5	259
25	Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Human Molecular Genetics, 2009, 18, 3039-3047.	1.4	255
26	De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nature Genetics, 1993, 5, 168-173.	9.4	251
27	Increased Platelet Aggregability Associated With Platelet <i> GPIIIa Pl ^{<i>A2</i>} Polymorphism </i> . Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1142-1147.	1.1	241
28	Juvenile onset Huntington's disease?clinical and research perspectives. Mental Retardation and Developmental Disabilities Research Reviews, 2001, 7, 153-157.	3.5	219
29	Genetic and Environmental Contributions to Platelet Aggregation. Circulation, 2001, 103, 3051-3056.	1.6	214
30	Familial aggregation of stroke. The Framingham Study Stroke, 1993, 24, 1366-1371.	1.0	212
31	Absence of Association or Genetic Linkage between the Angiotensin-Converting–Enzyme Gene and Left Ventricular Mass. New England Journal of Medicine, 1996, 334, 1023-1028.	13.9	212
32	Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus. Journal of Neuropathology and Experimental Neurology, 1991, 50, 729-742.	0.9	211
33	Factors Associated With Slow Progression in Huntington's Disease. Archives of Neurology, 1991, 48, 800-804.	4.9	196
34	Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: The Framingham study. Arthritis and Rheumatism, 1998, 41, 1064-1071.	6.7	188
35	Laboratory Guidelines for Huntington Disease Genetic Testing. American Journal of Human Genetics, 1998, 62, 1243-1247.	2.6	181
36	Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Human Molecular Genetics, 1995, 4, 1519-1526.	1.4	180

#	Article	IF	CITATIONS
37	Gametic but not somatic instability of CAG repeat length in Huntington's disease Journal of Medical Genetics, 1993, 30, 982-986.	1.5	175
38	A Genome-Wide Scan for Loci Linked to Plasma Levels of Glucose and HbA1c in a Community-Based Sample of Caucasian Pedigrees: The Framingham Offspring Study. Diabetes, 2002, 51, 833-840.	0.3	173
39	Directional dominance on stature and cognition inÂdiverse human populations. Nature, 2015, 523, 459-462.	13.7	173
40	Heritability of Left Ventricular Mass. Hypertension, 1997, 30, 1025-1028.	1.3	168
41	_{Predictive Testing for Huntingtons Disease with Use of a Linked DNA Marker} . New England Journal of Medicine, 1988, 318, 535-542.	13.9	167
42	Genome-Wide Association Studies Identify <i>CHRNA5/3</i> and <i>HTR4</i> in the Development of Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 622-632.	2.5	164
43	Quantitative neuropathological changes in presymptomatic Huntington's disease. Annals of Neurology, 2001, 49, 29-34.	2.8	163
44	The Huntington's disease candidate region exhibits many different haplotypes. Nature Genetics, 1992, 1, 99-103.	9.4	157
45	Coronary risk associated with age and sex of parental heart disease in the Framingham Study. American Journal of Cardiology, 1989, 64, 555-559.	0.7	156
46	Familial History of Stroke and Stroke Risk. Stroke, 1997, 28, 1908-1912.	1.0	154
47	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nature Communications, 2016, 7, 10494.	5.8	153
48	Attitudes toward presymptomatic testing in Huntington disease. American Journal of Medical Genetics Part A, 1987, 26, 271-282.	2.4	152
49	RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. PLoS ONE, 2015, 10, e0143563.	1.1	150
50	The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. Scientific Reports, 2017, 7, 1307.	1.6	150
51	A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study. American Journal of Human Genetics, 2003, 73, 682-687.	2.6	148
52	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. Archives of Neurology, 2006, 63, 826.	4.9	147
53	Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. Science, 1987, 238, 664-666.	6.0	145
54	Assessment of genetic risk for alzheimer's disease among first-degree relatives. Annals of Neurology, 1989, 25, 485-493.	2.8	145

#	Article	IF	CITATIONS
55	microRNA Profiles in Parkinson's Disease Prefrontal Cortex. Frontiers in Aging Neuroscience, 2016, 8, 36.	1.7	142
56	Quantitative-Trait Loci Influencing Body-Mass Index Reside on Chromosomes 7 and 13: The National Heart, Lung, and Blood Institute Family Heart Study. American Journal of Human Genetics, 2002, 70, 72-82.	2.6	138
57	Reduced Penetrance of the Huntington's Disease Mutation. Human Molecular Genetics, 1997, 6, 775-779.	1.4	131
58	The Bsml Vitamin D Receptor Restriction Fragment Length Polymorphism (bb) Influences the Effect of Calcium Intake on Bone Mineral Density. Journal of Bone and Mineral Research, 1997, 12, 1049-1057.	3.1	129
59	Genome Screen for Quantitative Trait Loci Contributing to Normal Variation in Bone Mineral Density: The Framingham Study. Journal of Bone and Mineral Research, 2002, 17, 1718-1727.	3.1	118
60	Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study. PLoS Medicine, 2013, 10, e1001462.	3.9	116
61	miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement. BMC Medical Genomics, 2015, 8, 10.	0.7	114
62	Human-Specific Histone Methylation Signatures at Transcription Start Sites in Prefrontal Neurons. PLoS Biology, 2012, 10, e1001427.	2.6	113
63	The Relationship Between CAG Repeat Length and Age of Onset Differs for Huntington's Disease Patients with Juvenile Onset or Adult Onset. Annals of Human Genetics, 2007, 71, 295-301.	0.3	110
64	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	0.9	104
65	Genomewide association study for onset age in Parkinson disease. BMC Medical Genetics, 2009, 10, 98.	2.1	104
66	Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease. BMC Medical Genomics, 2015, 9, 5.	0.7	103
67	Factors associated with HD CAG repeat instability in Huntington disease. Journal of Medical Genetics, 2007, 44, 695-701.	1.5	102
68	The Cly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Medicine, 2008, 6, 32.	2.3	102
69	Evidence for major genes influencing pulmonary function in the NHLBI Family Heart Study. Genetic Epidemiology, 2000, 19, 81-94.	0.6	101
70	Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3-qter: a genome-wide scan in the Framingham Study. Human Molecular Genetics, 2000, 9, 1315-1320.	1.4	100
71	Normal and Expanded Huntington's Disease Gene Alleles Produce Distinguishable Proteins Due to Translation Across the CAG Repeat. Molecular Medicine, 1995, 1, 374-383.	1.9	97
72	MicroRNAs Located in the Hox Gene Clusters Are Implicated in Huntington's Disease Pathogenesis. PLoS Genetics, 2014, 10, e1004188.	1.5	97

#	Article	IF	CITATIONS
73	PARK3 Influences Age at Onset in Parkinson Disease: A Genome Scan in the GenePD Study. American Journal of Human Genetics, 2002, 70, 1089-1095.	2.6	96
74	Segregation Analysis of Pulmonary Function among Families in the Framingham Study. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1445-1451.	2.5	94
75	Influence of Apolipoprotein E, Smoking, and Alcohol Intake on Carotid Atherosclerosis. Stroke, 2002, 33, 1357-1361.	1.0	93
76	Neocortical Dendritic Pathology in Human Partial Epilepsy: A Quantitative Golgi Study. Epilepsia, 1994, 35, 728-736.	2.6	92
77	Linkage Analysis of a Composite Factor for the Multiple Metabolic Syndrome: The National Heart, Lung, and Blood Institute Family Heart Study. Diabetes, 2003, 52, 2840-2847.	0.3	89
78	A modifier of Huntington's disease onset at the MLH1 locus. Human Molecular Genetics, 2017, 26, 3859-3867.	1.4	88
79	Common Variants in the 5′ Region of the Leptin Gene Are Associated with Body Mass Index in Men from the National Heart, Lung, and Blood Institute Family Heart Study. American Journal of Human Genetics, 2004, 75, 220-230.	2.6	86
80	Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. Nature Communications, 2018, 9, 2976.	5.8	85
81	Replication of Linkage of Familial Combined Hyperlipidemia to Chromosome 1q With Additional Heterogeneous Effect of Apolipoprotein A-I/C-III/A-IV Locus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2275-2280.	1.1	82
82	Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Human Molecular Genetics, 2006, 15, 2015-2024.	1.4	82
83	Genomewide Linkage Analysis to Presbycusis in the Framingham Heart Study. JAMA Otolaryngology, 2003, 129, 285.	1.5	81
84	Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis, 2001, 154, 747-754.	0.4	80
85	Family patterns of coronary heart disease mortality: The Framingham Longevity Study. Journal of Clinical Epidemiology, 1992, 45, 169-174.	2.4	79
86	Genetic Loci Influencing Lung Function. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 795-799.	2.5	79
87	Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiology of Disease, 1994, 1, 159-166.	2.1	77
88	Parental Age at Child's Birth and Son's Risk of Prostate Cancer: The Framingham Study. American Journal of Epidemiology, 1999, 150, 1208-1212.	1.6	76
89	Gene Expression Profiles in Parkinson Disease Prefrontal Cortex Implicate FOXO1 and Genes under Its Transcriptional Regulation. PLoS Genetics, 2012, 8, e1002794.	1.5	76
90	Conserved Higher-Order Chromatin Regulates NMDA Receptor Gene Expression and Cognition. Neuron, 2014, 84, 997-1008.	3.8	76

#	Article	IF	CITATIONS
91	Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study. BMC Medical Genetics, 2006, 7, 71.	2.1	72
92	Familial Alzheimer's disease: Progress and problems. Neurobiology of Aging, 1989, 10, 417-425.	1.5	69
93	DNM3 and genetic modifiers of age of onset in LRRK2 Cly2019Ser parkinsonism: a genome-wide linkage and association study. Lancet Neurology, The, 2016, 15, 1248-1256.	4.9	69
94	Evidence of presymptomatic cognitive decline in Huntington's disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1992, 14, 961-975.	1.4	67
95	Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics, 2004, 5, 109-114.	0.7	67
96	Copy Number Variation in Familial Parkinson Disease. PLoS ONE, 2011, 6, e20988.	1.1	67
97	Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains. Human Molecular Genetics, 2015, 24, 1441-1456.	1.4	67
98	MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology, 2018, 90, e264-e272.	1.5	65
99	Understanding the decision to take the predictive test for Huntington disease. American Journal of Medical Genetics Part A, 1991, 39, 404-410.	2.4	64
100	Genome-Wide Linkage Analysis of Lipids in the Hypertension Genetic Epidemiology Network (HyperGEN) Blood Pressure Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1969-1976.	1.1	64
101	Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. Movement Disorders, 1996, 11, 671-677.	2.2	61
102	Leptin Is Associated With Blood Pressure and Hypertension in Women From the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension, 2009, 53, 473-479.	1.3	61
103	Mapping of Quantitative Ultrasound of the Calcaneus Bone to Chromosome 1 by Genome-Wide Linkage Analysis. Osteoporosis International, 2002, 13, 796-802.	1.3	60
104	Cyclin-G-associated kinase modifies Â-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Human Molecular Genetics, 2011, 20, 1478-1487.	1.4	60
105	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012, 90, 434-444.	2.6	60
106	Genome Scan for Quantitative Trait Loci Linked to High-Density Lipoprotein Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1823-1828.	1.1	59
107	Heritability of Longitudinal Change in Lung Function. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1655-1659.	2.5	59
108	Huntington disease: No evidence for locus heterogeneity. Genomics, 1989, 5, 304-308.	1.3	56

7

#	Article	IF	CITATIONS
109	Longitudinal and age trends of metabolic syndrome and its risk factors: The Family Heart Study. Nutrition and Metabolism, 2006, 3, 41.	1.3	56
110	Genetic Effect on Blood Pressure Is Modulated by Age. Hypertension, 2009, 53, 35-41.	1.3	56
111	Interaction of α ₁ -Na,K-ATPase and Na,K,2Cl-Cotransporter Genes in Human Essential Hypertension. Hypertension, 2001, 38, 204-209.	1.3	53
112	Assessment of cortical and striatal involvement in 523 Huntington disease brains. Neurology, 2012, 79, 1708-1715.	1.5	52
113	Genetic Variability of Adult Body Mass Index: A Longitudinal Assessment in Framingham Families. Obesity, 2002, 10, 675-681.	4.0	51
114	Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27–35 CAG). American Journal of Medical Genetics, Part A, 2009, 149A, 1375-1381.	0.7	48
115	The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease. PLoS ONE, 2015, 10, e0144398.	1.1	47
116	Potential impact of a predictive test on the gene frequency of Huntington disease. American Journal of Medical Genetics Part A, 1984, 18, 423-429.	2.4	46
117	β-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-α-lipoproteinaemia. Lancet, The, 1998, 351, 1919-1923.	6.3	46
118	A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study. Diabetologia, 2003, 46, 579-587.	2.9	46
119	A Genome-Wide Scan of Pulmonary Function Measures in the National Heart, Lung, and Blood Institute Family Heart Study. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1528-1533.	2.5	43
120	Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease. Experimental Neurology, 2010, 226, 207-217.	2.0	43
121	Monozygotic Twins Discordant for Huntington Disease After 7 Years. Archives of Neurology, 2005, 62, 995-7.	4.9	42
122	Novel Genetic Variants Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of <i>SLC1A3</i> and <i>EPHB2</i> . Journal of Bone and Mineral Research, 2016, 31, 2085-2097.	3.1	42
123	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	0.9	41
124	State of the art review: Molecular diagnosis of inherited movement disorders.MovementDisorders Society task force on molecular diagnosis. Movement Disorders, 2003, 18, 3-18.	2.2	40
125	An evaluation of the metabolic syndrome in the HyperGEN study. Nutrition and Metabolism, 2005, 2, 2.	1.3	40
126	Combined analysis of genomewide scans for adult height: results from the NHLBI Family Blood Pressure Program. European Journal of Human Genetics, 2003, 11, 271-274.	1.4	39

#	Article	IF	CITATIONS
127	Correction for multiple testing in a gene region. European Journal of Human Genetics, 2014, 22, 414-418.	1.4	39
128	A glycomics and proteomics study of aging and Parkinson's disease in human brain. Scientific Reports, 2020, 10, 12804.	1.6	37
129	Alzheimer's Disease, Down's Syndrome, and Aging: The Genetic Approach. Annals of the New York Academy of Sciences, 1982, 396, 3-13.	1.8	36
130	Evaluation of Parkinson Disease Risk Variants as Expression-QTLs. PLoS ONE, 2012, 7, e46199.	1.1	36
131	Study of plasmaâ€derived miRNAs mimic differences in Huntington's disease brain. Movement Disorders, 2015, 30, 1961-1964.	2.2	36
132	Novel microRNA discovery using small RNA sequencing in post-mortem human brain. BMC Genomics, 2016, 17, 776.	1.2	36
133	The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntington's disease brain. BMC Medical Genomics, 2019, 12, 137.	0.7	36
134	Huntington's disease in monozygotic twins reared apart Journal of Medical Genetics, 1983, 20, 408-411.	1.5	35
135	Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study. American Journal of Clinical Nutrition, 2004, 80, 1639-1644.	2.2	35
136	Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136 → Ser) variant in multigenerational pedigree studies. Atherosclerosis, 1996, 122, 33-46.	0.4	34
137	Linkage and association with pulmonary function measures on chromosome 6q27 in the Framingham Heart Study. Human Molecular Genetics, 2003, 12, 2745-2751.	1.4	34
138	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Human Genetics, 2008, 124, 95-99.	1.8	34
139	Long-term impact of Huntington disease linkage testing. , 1997, 70, 365-370.		33
140	Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: The atherosclerosis risk in communities and the NHLBI family heart studies. Atherosclerosis, 1998, 138, 111-116.	0.4	33
141	Risk of Parkinson's disease after tamoxifen treatment. BMC Neurology, 2010, 10, 23.	0.8	33
142	Considerations for Genomewide Association Studies in Parkinson Disease. American Journal of Human Genetics, 2006, 78, 1081-1082.	2.6	32
143	Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles. Frontiers in Molecular Neuroscience, 2017, 10, 430.	1.4	32
144	Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiology of Disease, 2006, 24, 280-285.	2.1	31

#	Article	IF	CITATIONS
	Lewis blood group phenotype as an independent risk factor for coronary heart disease (the NHLBI) Tj ETQq1	1 0.784314 r	gBT /Overlock
145	Journal of Cardiology, 1999, 83, 345-348.	0.7	30
146	Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study. American Journal of Hypertension, 2004, 17, 839-844.	1.0	30
147	Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. Brain Research, 2007, 1139, 42-47.	1.1	30
148	The Genetic Modifiers of Motor OnsetAgeÂ(GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. Journal of Huntington's Disease, 2015, 4, 279-284.	0.9	30
149	Genomewide Association Studies of <scp><i>LRRK2</i></scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	2.8	30
150	Effects of Similarities in Lifestyle Habits on Familial Aggregation of High Density Lipoprotein and Low Density Lipoprotein Cholesterol: The NHLBI Family Heart Study. American Journal of Epidemiology, 1999, 150, 910-918.	1.6	29
151	Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease. Biological Psychiatry, 2020, 87, 857-865.	0.7	29
152	Is DFNA5 a susceptibility gene for age-related hearing impairment?. European Journal of Human Genetics, 2002, 10, 883-886.	1.4	27
153	Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI Family Heart Study. Journal of Internal Medicine, 2000, 247, 689-698.	2.7	26
154	A genome-wide screen reveals evidence for a locus on chromosomeÂ11 influencing variation in LDL cholesterol in the NHLBI Family Heart Study. Human Genetics, 2002, 111, 263-269.	1.8	26
155	Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics, 2012, 131, 1833-1840.	1.8	26
156	Evidence for a gene influencing heart rate on chromosome 4 among hypertensives. Human Genetics, 2002, 111, 207-213.	1.8	25
157	A Genome-Wide Scan for Loci Affecting Normal Adult Height in the Framingham Heart Study. Human Heredity, 2003, 55, 191-201.	0.4	25
158	Adrenergic Receptor Polymorphisms Associated with Resting Heart Rate: The HyperGEN Study. Annals of Human Genetics, 2006, 70, 566-573.	0.3	25
159	Quantitative Trait Loci for Metabolic Syndrome in the Hypertension Genetic Epidemiology Network Study. Obesity, 2005, 13, 1885-1890.	4.0	24
160	Haplotype-based stratification of Huntington's disease. European Journal of Human Genetics, 2017, 25, 1202-1209.	1.4	24
161	Considerations in using linkage analysis as a presymptomatic test for Huntington's disease Journal of Medical Genetics, 1988, 25, 577-588.	1.5	22
162	Polymorphisms near EXOC4 and LRGUK on chromosome 7q32 are associated with Type 2 Diabetes and fasting glucose; The NHLBI Family Heart Study. BMC Medical Genetics, 2008, 9, 46.	2.1	22

#	Article	IF	CITATIONS
163	Sequence-Level Analysis of the Major European Huntington Disease Haplotype. American Journal of Human Genetics, 2015, 97, 435-444.	2.6	22
164	Change in attitudes toward presymptomatic testing in Huntington disease. American Journal of Medical Genetics Part A, 1986, 24, 369-371.	2.4	21
165	Genotype-by-sex interaction in the aetiology of type 2 diabetes mellitus: support for sex-specific quantitative trait loci in Hypertension Genetic Epidemiology Network participants. Diabetologia, 2006, 49, 2329-2336.	2.9	21
166	Evaluation of logistic regression models and effect of covariates for case–control study in RNA-Seq analysis. BMC Bioinformatics, 2017, 18, 91.	1.2	21
167	The 4p16.3 Parkinson Disease Risk Locus Is Associated with GAK Expression and Genes Involved with the Synaptic Vesicle Membrane. PLoS ONE, 2016, 11, e0160925.	1.1	21
168	Absence of linkage or association for osteoarthritis with the vitamin D receptor/type II collagen locus: the Framingham Osteoarthritis Study. Journal of Rheumatology, 2002, 29, 161-5.	1.0	21
169	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	1.0	20
170	Linkage Analysis of Diabetes Status Among Hypertensive Families: The Hypertension Genetic Epidemiology Network Study. Diabetes, 2004, 53, 3307-3312.	0.3	19
171	Genotype-by-Sex Interaction on Fasting Insulin Concentration: The HyperGEN Study. Diabetes, 2007, 56, 137-142.	0.3	19
172	Evidence of Extensive Alternative Splicing in Post Mortem Human Brain HTT Transcription by mRNA Sequencing. PLoS ONE, 2015, 10, e0141298.	1.1	19
173	Estimation of fertility and fitness in Huntington disease in New England. American Journal of Medical Genetics Part A, 1989, 33, 248-254.	2.4	18
174	Smoking influences the association between apolipoprotein E and lipids: The national heart, lung, and blood institute family heart study. Lipids, 2000, 35, 827-831.	0.7	17
175	Quantitative Trait Loci on Chromosome 8q24 for Pancreatic Â-Cell Function and 7q11 for Insulin Sensitivity in Obese Nondiabetic White and Black Families: Evidence From Genome-Wide Linkage Scans in the NHLBI Hypertension Genetic Epidemiology Network (HyperGEN) Study. Diabetes, 2006, 55, 551-558.	0.3	17
176	Circulating MCP-1 levels shows linkage to chemokine receptor gene cluster on chromosome 3: the NHLBI Family Heart Study follow-up examination. Genes and Immunity, 2007, 8, 684-690.	2.2	17
177	Multiple Genes Influence BMI on Chromosome 7q31–34: The NHLBI Family Heart Study. Obesity, 2009, 17, 2182-2189.	1.5	17
178	Absence of effect of seven functional mutations in the cyp2d6 gene in Parkinson's disease. Movement Disorders, 1999, 14, 590-595.	2.2	16
179	Genetic analysis of the GRIK2 modifier effect in Huntington's disease. BMC Neuroscience, 2006, 7, 62.	0.8	16
180	Circulating soluble ICAM-1 levels shows linkage to ICAM gene cluster region on chromosome 19: The NHLBI Family Heart Study follow-up examination. Atherosclerosis, 2008, 199, 172-178.	0.4	16

#	Article	IF	CITATIONS
181	Using survival methods to estimate age-at-onset distributions for genetic diseases with an application to Huntington disease. Genetic Epidemiology, 1989, 6, 361-371.	0.6	15
182	LIPC variants in the promoter and intron 1 modify HDL-C levels in a sex-specific fashion. Atherosclerosis, 2009, 204, 171-177.	0.4	15
183	Absence of Linkage for Bone Mineral Density to Chromosome 12q12-14 in the Region of the Vitamin D Receptor Gene. Calcified Tissue International, 2000, 67, 434-439.	1.5	14
184	Genome-Wide Scan Identifies Novel QTLs for Cholesterol and LDL Levels in F2[Dahl R×S]-Intercross Rats. Circulation Research, 2004, 94, 446-452.	2.0	14
185	HaploBuild: an algorithm to construct non-contiguous associated haplotypes in family based genetic studies. Bioinformatics, 2007, 23, 2190-2192.	1.8	13
186	Segregation analysis for high density lipoprotein in the berkeley data. Genetic Epidemiology, 1993, 10, 629-634.	0.6	12
187	Evidence for a major gene accounting for mild elevation in LDL cholesterol: The NHLBI Family Heart Study. Annals of Human Genetics, 1999, 63, 401-412.	0.3	12
188	Insulin and hypertension in the NHLBI family heart study: A sibpair approach to a controversial issue. American Journal of Hypertension, 2000, 13, 240-250.	1.0	11
189	A Haplotype Similarity Based Transmission/Disequilibrium Test under Founder Heterogeneity. Annals of Human Genetics, 2005, 69, 455-467.	0.3	11
190	Evidence for a gene influencing heart rate on chromosome 5p13-14 in a meta-analysis of genome-wide scans from the NHLBI Family Blood Pressure Program. BMC Medical Genetics, 2006, 7, 17.	2.1	11
191	Genomeâ€wide admixture mapping for coronary artery calcification in African Americans: the NHLBI Family Heart Study. Genetic Epidemiology, 2008, 32, 264-272.	0.6	11
192	Postmortem Interval Influences <i>α</i> -Synuclein Expression in Parkinson Disease Brain. Parkinson's Disease, 2012, 2012, 1-8.	0.6	11
193	Attitudes Toward Marriage and Childbearing of Individuals at Risk for Huntington's Disease. Social Work in Health Care, 1984, 9, 73-81.	0.8	10
194	A QTL on 12q Influencing an Inflammation Marker and Obesity in White Women: The NHLBI Family Heart Study. Obesity, 2009, 17, 525-531.	1.5	10
195	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics, 2013, 14, 173-179.	0.7	10
196	NYD-SP18 is associated with obesity in the NHLBI Family Heart Study. International Journal of Obesity, 2008, 32, 930-935.	1.6	9
197	LRRK2 is not a Significant Cause of Parkinson's Disease in French-Canadians. Canadian Journal of Neurological Sciences, 2007, 34, 333-335.	0.3	8
198	Evidence of QTL on 15q21 for high-density lipoprotein cholesterol: The National Heart, Lung, and Blood Institute Family Heart Study (NHLBI FHS). Atherosclerosis, 2007, 190, 232-237.	0.4	8

#	Article	IF	CITATIONS
199	Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The <i>Gene</i> PD study. Movement Disorders, 2008, 23, 1596-1601.	2.2	8
200	Genomewide linkage study of modifiers of <i>LRRK2</i> â€related Parkinson's disease. Movement Disorders, 2011, 26, 2039-2044.	2.2	8
201	Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease. Progress in Neurobiology, 2021, 204, 102110.	2.8	8
202	Learned aversions to intracerebral carbachol. Physiology and Behavior, 1977, 19, 467-472.	1.0	7
203	Estrogen-related and other disease diagnoses preceding Parkinson's disease. Clinical Epidemiology, 2010, 2, 153.	1.5	7
204	Comprehensive linkage and linkage heterogeneity analysis of 4344 sibling pairs affected with hypertension from the Family Blood Pressure Program. Genetic Epidemiology, 2007, 31, 195-210.	0.6	6
205	Discrepancy resolved. Nature Genetics, 1993, 5, 215-215.	9.4	5
206	The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms. Statistics in Medicine, 2003, 22, 3249-3262.	0.8	5
207	Huntington's Disease: Neuropathological Grading. Advances in Behavioral Biology, 1987, , 515-531.	0.2	5
208	Estimation of familial risk in Alzheimer's disease. Annals of Neurology, 1990, 27, 338-340.	2.8	4
209	Evidence for Three Novel QTLs for Adiposity on Chromosome 2 With Epistatic Interactions: The NHLBI Family Heart Study. Obesity, 2009, 17, 2190-2195.	1.5	4
210	Effects of Age and Ethnicity on the Link Between <i>APOE ϵ4</i> and Alzheimer Disease—Reply. JAMA - Journal of the American Medical Association, 1998, 279, 581.	3.8	4
211	Feasibility of Huntington disease trials in the disease prodrome. Neurology, 2014, 82, 824-825.	1.5	3
212	Segregation analysis of total nevus density and estimation of lifetime risk and average onset age of melanoma. Cytogenetic and Genome Research, 1992, 59, 197-199.	0.6	2
213	Huntington's disease genetics. Neurotherapeutics, 2004, 1, 255-262.	2.1	2
214	Detecting linkage for a complex disease using simulated extended pedigrees. Genetic Epidemiology, 1997, 14, 981-986.	0.6	1
215	No evidence of linkage between the very—low-density lipoprotein receptor gene and fasting serum insulin or homeostasis model assessment insulin resistance index: The National Heart, Lung, and Blood Institute Family Heart Study. Metabolism: Clinical and Experimental, 2000, 49, 293-297.	1.5	1
216	The Association of Cell Cycle Checkpoint 2 Variants and Kidney Function: Findings of the Family Blood Pressure Program and the Atherosclerosis Risk in Communities Study. American Journal of Hypertension, 2009, 22, 552-558.	1.0	1

#	Article	IF	CITATIONS
217	Huntington's Disease. , 2017, , 503-516.		1
218	B4â€Detection of the aberrantly spliced exon 1 – intron 1 htt mRNA in HD patient post mortem brain tissue and fibroblast lines. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A10.2-A10.	0.9	0